These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18926156)

  • 21. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
    Kovarik JM; Snell GI; Valentine V; Aris R; Chan CK; Schmidli H; Pirron U
    J Heart Lung Transplant; 2006 Apr; 25(4):440-6. PubMed ID: 16563975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute coronary syndrome is an independent risk factor for late incomplete stent apposition after sirolimus-eluting stent implantation.
    Zhang RY; DU R; Zhu ZB; Zhang Q; Hu J; Lü AK; Zhang JS; Shen WF
    Chin Med J (Engl); 2008 Dec; 121(24):2504-8. PubMed ID: 19187586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
    Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
    Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database.
    Liu HB; Xu B; Yang YJ; Wang Y; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Ma WH; Li JJ; Qiao SB; Chen JL; Li W; Gao RL
    Chin Med J (Engl); 2009 Mar; 122(6):681-6. PubMed ID: 19323934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor.
    Brandhorst G; Tenderich G; Zittermann A; Oezpeker C; Koerfer R; Oellerich M; Armstrong VW
    Ther Drug Monit; 2008 Feb; 30(1):113-6. PubMed ID: 18223473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the systemic levels of inflammatory markers after percutaneous coronary intervention with bare metal versus sirolimus-eluting stents.
    Rebeiz AG; Zoghbi E; Harb R; Youhanna S; Skouri HN; Dimassi A; Abou-Nader G; Nasrallah A; Sawaya J; Gharzuddine W; Alam S
    J Interv Cardiol; 2009 Apr; 22(2):169-74. PubMed ID: 19245380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients.
    Otsuka Y; Saito S; Nakamura M; Shuto H; Mitsudo K
    Catheter Cardiovasc Interv; 2011 Dec; 78(7):1078-85. PubMed ID: 21538783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
    Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
    Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Alfonso F; Pérez-Vizcayno MJ; Hernández R; Bethencourt A; Martí V; López-Mínguez JR; Angel J; Iñiguez A; Morís C; Cequier A; Sabaté M; Escaned J; Jiménez-Quevedo P; Bañuelos C; Suárez A; Macaya C;
    J Am Coll Cardiol; 2008 Nov; 52(20):1621-7. PubMed ID: 18992651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction.
    Kim JW; Seo HS; Park JH; Na JO; Choi CU; Lim HE; Kim EJ; Rha SW; Park CG; Oh DJ
    J Am Coll Cardiol; 2009 May; 53(18):1653-9. PubMed ID: 19406340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings.
    Harjai KJ; Orshaw P; Boura J; Sporn D
    Am J Cardiol; 2009 Jun; 103(11):1537-45. PubMed ID: 19463512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression.
    Chen YW; Smith ML; Sheets M; Ballaron S; Trevillyan JM; Burke SE; Rosenberg T; Henry C; Wagner R; Bauch J; Marsh K; Fey TA; Hsieh G; Gauvin D; Mollison KW; Carter GW; Djuric SW
    J Cardiovasc Pharmacol; 2007 Apr; 49(4):228-35. PubMed ID: 17438408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sirolimus-eluting stent treatment at high-volume centers confers lower mortality at 6-month follow-up: results from the prospective multicenter German Cypher Registry.
    Khattab AA; Hamm CW; Senges J; Toelg R; Geist V; Bonzel T; Kelm M; Levenson B; Nienaber CA; Pfannebecker T; Sabin G; Schneider S; Tebbe U; Neumann FJ; Richardt G;
    Circulation; 2009 Aug; 120(7):600-6. PubMed ID: 19652087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Internal standard selection for the high-performance liquid chromatography tandem mass spectroscopy assay of everolimus in blood.
    Hoogtanders K; van der Heijden J; Stolk LM; Neef C; Christiaans M; van Hooff J
    Ther Drug Monit; 2007 Oct; 29(5):673-4. PubMed ID: 17898665
    [No Abstract]   [Full Text] [Related]  

  • 40. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.
    Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M
    Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.